Form 4: Aclaris CFO Balthaser Acquires Shares via RSU Vesting

Aclaris Therapeutics' CFO, Kevin Balthaser, acquired 22,025 shares of common stock through the vesting of restricted stock units, with a portion withheld for tax obligations.

Summary

• Kevin Balthaser, Chief Financial Officer of Aclaris Therapeutics, Inc., acquired 22,025 shares of common stock on February 3, 2026, through the vesting of restricted stock units.
• Concurrently, 6,449 shares were withheld by the issuer at a price of $3.47 per share to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, Mr. Balthaser directly beneficially owns 185,755 shares of common stock.
• He also holds 66,075 restricted stock units, which are scheduled to vest in four equal annual installments on the first, second, third, and fourth anniversaries of February 3, 2025, subject to his continuous service.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a routine and expected insider transaction related to executive compensation, reflecting the ongoing retention of a key financial officer.

Positives

• The vesting of restricted stock units indicates continued retention and alignment of a key executive, the Chief Financial Officer, with shareholder interests.
• The acquisition of shares through vesting increases the CFO's direct ownership in the company.

Negatives

• A portion of the shares (6,449) was sold to cover tax liabilities, which is a common practice but reduces the net shares acquired by the executive.

Future Outlook

The remaining 66,075 restricted stock units held by Kevin Balthaser are scheduled to vest in four equal annual installments on the first, second, third, and fourth anniversaries of February 3, 2025, contingent on his continuous service to the company.

Industry Context

StockSavvy.ai notes that executive compensation often includes restricted stock units (RSUs) to align management incentives with long-term shareholder value. The vesting of these units, as seen with Aclaris Therapeutics' CFO, is a standard component of such compensation plans, reflecting the executive's continued service and the company's commitment to retaining key talent.

Comparison to Industry Standards

• Executive compensation structures, including RSU grants and vesting schedules, are common across the biotechnology and pharmaceutical industries. For example, similar RSU vesting events are routinely reported by executives at companies like Moderna (MRNA) or Pfizer (PFE), where equity-based incentives are a significant part of total compensation.
• The practice of withholding shares for tax purposes upon vesting is also a standard industry practice to manage tax liabilities efficiently.

Related Party Transactions

• The vesting and settlement of restricted stock units for the Chief Financial Officer constitute a related party transaction between the company and a key executive.

Stakeholder Impact

• Shareholders: The issuance of new shares upon RSU vesting can lead to minor dilution, but the retention of a key executive like the CFO is generally positive for long-term stability and strategic execution.
• Employees: This transaction highlights the company's executive compensation structure, which may influence broader employee compensation strategies and morale.

Next Steps

• Future vesting of 66,075 restricted stock units in four equal annual installments on the anniversaries of February 3, 2025, subject to continuous service.

Key Dates

Keywords

Aclaris Therapeutics, ACRS, Kevin Balthaser, Chief Financial Officer, CFO, Restricted Stock Units, RSU vesting, Insider transaction, Stock acquisition, Executive compensation, Form 4, Beneficial ownership